|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Castellsague X: Natural history and
epidemiology of HPV infection and cervical cancer. Gynecol Oncol
110 (3 Suppl 2). S4–S7. 2008. View Article : Google Scholar
|
|
4
|
Du CX and Wang Y: Expression of P-Akt,
NFkappaB and their correlation with human papillomavirus infection
in cervical carcinoma. Eur J Gynaecol Oncol. 33:274–277.
2012.PubMed/NCBI
|
|
5
|
Ghebre RG, Grover S, Xu MJ, Chuang LT and
Simonds H: Cervical cancer control in HIV-infected women: Past,
present and future. Gynecol Oncol Rep. 21:101–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hildesheim A and Wang SS: Host and viral
genetics and risk of cervical cancer: A review. Virus Res.
89:229–240. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Link A and Kupcinskas J: MicroRNAs as
non-invasive diagnostic biomarkers for gastric cancer: Current
insights and future perspectives. World J Gastroenterol.
24:3313–3329. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
To KK, Tong CW, Wu M and Cho WC: MicroRNAs
in the prognosis and therapy of colorectal cancer: From bench to
bedside. World J Gastroenterol. 24:2949–2973. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, Li B and Xie X: The roles and
clinical significance of microRNAs in cervical cancer. Histol
Histopathol. 31:131–139. 2016.PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He L and Hannon GJ: MicroRNAs: small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kozomara A and Griffiths-Jones S: miRBase:
Annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res. 42:D68–D73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laengsri V, Kerdpin U, Plabplueng C,
Treeratanapiboon L and Nuchnoi P: Cervical Cancer Markers:
Epigenetics and microRNAs. Lab Med. 49:97–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X
and Cong H: The potential function of microRNAs as biomarkers and
therapeutic targets in multiple myeloma. Oncol Lett. 15:6094–6106.
2018.PubMed/NCBI
|
|
16
|
Lu J, Zhan Y, Feng J, Luo J and Fan S:
MicroRNAs associated with therapy of non-small cell lung cancer.
Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai N, Hu L, Xie Y, Gao JH, Zhai W, Wang
L, Jin QJ, Qin CY and Qiang R: MiR-17-5p promotes cervical cancer
cell proliferation and metastasis by targeting transforming growth
factor-beta receptor 2. Eur Rev Med Pharmacol Sci. 22:1899–1906.
2018.PubMed/NCBI
|
|
18
|
Li GC, Cao XY, Li YN, Qiu YY, Li YN, Liu
XJ and Sun XX: MicroRNA-374b inhibits cervical cancer cell
proliferation and induces apoptosis through the p38/ERK signaling
pathway by binding to JAM-2. J Cell Physiol. 233:7379–7390. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanches JGP, Xu Y, Yabasin IB, Li M, Lu Y,
Xiu X, Wang L, Mao L, Shen J, Wang B, et al: miR-501 is upregulated
in cervical cancer and promotes cell proliferation, migration and
invasion by targeting CYLD. Chem Biol Interact. 285:85–95. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Y, He J, Wang Y, Zhu X, Pan Q, Xie Q
and Sun F: miR-889 promotes proliferation of esophageal squamous
cell carcinomas through DAB2IP. FEBS Lett. 589:1127–1135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie H, Zhang Q, Zhou H, Zhou J, Zhang J,
Jiang Y, Wang J, Meng X, Zeng L and Jiang X: microRNA-889 is
downregulated by histone deacetylase inhibitors and confers
resistance to natural killer cytotoxicity in hepatocellular
carcinoma cells. Cytotechnology. 70:513–521. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cha Y, Kim HP, Lim Y, Han SW, Song SH and
Kim TY: FGFR2 amplification is predictive of sensitivity to
regorafenib in gastric and colorectal cancers in vitro. Mol
Oncol. 12:993–1003. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fu YT, Zheng HB, Zhang DQ, Zhou L and Sun
H: MicroRNA-1266 suppresses papillary thyroid carcinoma cell
metastasis and growth via targeting FGFR2. Eur Rev Med Pharmacol
Sci. 22:3430–3438. 2018.PubMed/NCBI
|
|
24
|
Marzioni D, Lorenzi T, Mazzucchelli R,
Capparuccia L, Morroni M, Fiorini R, Bracalenti C, Catalano A,
David G, Castellucci M, et al: Expression of basic fibroblast
growth factor, its receptors and syndecans in bladder cancer. Int J
Immunopathol Pharmacol. 22:627–638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lei H and Deng CX: Fibroblast growth
factor receptor 2 signaling in breast cancer. Int J Biol Sci.
13:1163–1171. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi CH, Chung JY, Kim JH, Kim BG and
Hewitt SM: Expression of fibroblast growth factor receptor family
members is associated with prognosis in early stage cervical cancer
patients. J Transl Med. 14:1242016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kawase R, Ishiwata T, Matsuda Y, Onda M,
Kudo M, Takeshita T and Naito Z: Expression of fibroblast growth
factor receptor 2 IIIc in human uterine cervical intraepithelial
neoplasia and cervical cancer. Int J Oncol. 36:331–340.
2010.PubMed/NCBI
|
|
29
|
Li M, Qian Z, Ma X, Lin X, You Y, Li Y,
Chen T and Jiang H: MiR-628-5p decreases the tumorigenicity of
epithelial ovarian cancer cells by targeting at FGFR2. Biochem
Biophys Res Commun. 495:2085–2091. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang X, Ruan H, Hu X, Cao A and Song L:
miR-381-3p suppresses the proliferation of oral squamous cell
carcinoma cells by directly targeting FGFR2. Am J Cancer Res.
7:913–922. 2017.PubMed/NCBI
|
|
31
|
Wang JY and Chen LJ: The role of miRNAs in
the invasion and metastasis of cervical cancer. Biosci Rep.
39:2019.
|
|
32
|
Pedroza-Torres A, Lopez-Urrutia E,
Garcia-Castillo V, Jacobo-Herrera N, Herrera LA, Peralta-Zaragoza
O, López-Camarillo C, De Leon DC, Fernández-Retana J, Cerna-Cortés
JF and Pérez-Plasencia C: MicroRNAs in cervical cancer: Evidences
for a miRNA profile deregulated by HPV and its impact on
radio-resistance. Molecules. 19:6263–6281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Banno K, Iida M, Yanokura M, Kisu I, Iwata
T, Tominaga E, Tanaka K and Aoki D: MicroRNA in cervical cancer:
OncomiRs and tumor suppressor miRs in diagnosis and treatment.
TheScientificWorldJournal. 2014:1780752014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shishodia G, Verma G, Das BC and Bharti
AC: miRNA as viral transcription tuners in HPV-mediated cervical
carcinogenesis. Front Biosci (Schol Ed). 10:21–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Katoh Y and Katoh M: FGFR2-related
pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol
Med. 23:626–639. 2018.
|
|
36
|
Ishiwata T: Role of fibroblast growth
factor receptor-2 splicing in normal and cancer cells. Front Biosci
(Landmark Ed). 23:626–639. 2018. View
Article : Google Scholar : PubMed/NCBI
|
